PCSK9 Inhibitors in Prevention: How to Use Them Like the Experts

PCSK9 Inhibitors in Prevention: How to Use Them Like the Experts is organized by Vindico Medical Education.

 

Release Date: 8/31/2018

Expiration Date: 8/30/2019

 

The intended audience for this activity is cardiologists and other health care professionals involved in the treatment of patients with dyslipidemia.

 

This CME Conference has been approved for a maximum of 1.0 AMA PRA Category 1 Credits™.

 

As clinical data emerge regarding the benefit of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, obtaining access to these agents remains a barrier to their use. Given the high prevalence of patients on statin therapy who fail to meet low-density lipoprotein cholesterol (LDL-C) target goals, continuing education is crucial regarding the latest clinical advances and recommendations for the use of PCSK9 inhibitors, as well as practical strategies to gain access to these agents to improve patient outcomes. This educational activity will feature a panel of experts who will review the latest recommendations for the use of PCSK9 inhibitors in prevention and the impact of their use on cardiovascular outcomes. They will also assess the latest data on the benefits and safety of achieving low LDL-C goals, as well as detail practical strategies to improve access to treatment. Clinical cases will be presented to highlight the key educational objectives.

 

Upon successful completion of this activity, participants should be better able to:

• Identify patients with hypercholesterolemia who may benefit from LDL-C reduction with a PCSK9 inhibitor.

• Utilize PCSK9 inhibitors in accordance with the latest clinical evidence.

• Implement appropriate strategies to improve access to PCSK9 inhibitors.